NEW YORK, May 4, 2018 /PRNewswire/ -- If you want a free Stock Review on MNKD, MRNS, MRTX, and ONCS sign up now at www.wallstequities.com/registration.WallStEquities.com has initiated research coverage on MannKind Corp. (NASDAQ: MNKD), Marinus Pharmaceuticals Inc. (NASDAQ: MRNS), Mirati Therapeutics Inc. (NASDAQ: MRTX), and OncoSec Medical Inc. (NASDAQ: ONCS). Companies in the Biotechnology industry
Westlake Village, California headquartered MannKind Corp.'s stock finished Thursday's session 2.35% higher at $1.74 with a total trading volume of 1.03 million shares. Over the past year, the Company's shares have surged 146.74%. The stock is trading below its 50-day moving average by 24.12%. Moreover, shares of MannKind, which focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients, have a Relative Strength Index (RSI) of 38.48.
On May 02nd, 2018, MannKind announced the release of its Q1 2018 financial results on May 09th, 2018. Management will host a conference call at 5:00 p.m. ET that same day to discuss the results and other Company developments. Presenting from the Company will be CEO, Michael Castagna; CFO, Steven Binder; Chief Commercial Officer, Pat McCauley; and Chief Medical Officer, David Kendall. Get the full research report on MNKD for free by clicking below at: www.wallstequities.com/registration/?symbol=MNKD
Shares in Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc. rose 1.27%, ending yesterday's session at $4.80 with a total trading volume of 385,664 shares. The stock has gained 15.66% in the past month and 263.64% over the past year. The Company's shares are trading 6.49% above their 50-day moving average. Moreover, shares of Marinus Pharmaceuticals, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, have an RSI of 58.63.
On May 02nd, 2018, Marinus Pharma reported its financial results for the quarter ended March 31st, 2018. R&D expenses for Q1 2018 were $3.9 million; and G&A expenses were $2.2 million. At March 31st, 2018, the Company had cash, cash equivalents, and investments of $52.0 million, compared to $58.4 million at December 31st, 2017. Find your free research report on MRNS at: www.wallstequities.com/registration/?symbol=MRNSMirati Therapeutics
On Thursday, San Diego, California headquartered Mirati Therapeutics Inc.'s stock dropped 1.32%, to close the day at $33.75. A total volume of 315,577 shares was traded. The Company's shares have advanced 20.11% in the last month, 26.88% in the previous three months, and 723.17% over the past year. The stock is trading 11.11% and 83.30% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Mirati Therapeutics, which develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer, have an RSI of 61.41.
On April 24th, 2018, Mirati Therapeutics announced updated, positive clinical trial data for sitravatinib, a spectrum selective kinase inhibitor. As of March 31st, 2018, 23 patients were evaluable for response with at least one radiographic scan, six patients achieved a partial response (four confirmed and two unconfirmed), and 19 of 23 patients demonstrated tumor reductions. To date, the combination has been well tolerated, and most adverse events reported by investigators were Grade 1 or 2. Sign up today for the free research report on MRTX at: www.wallstequities.com/registration/?symbol=MRTX
Shares in San Diego, California headquartered OncoSec Medical Inc. ended the day 2.00% lower at $1.47. A total volume of 392,629 shares was traded. The stock has gained 30.09% over the past year. The Company's shares are trading below their 200-day moving average by 4.04%. Furthermore, shares of OncoSec Medical, which engages in developing DNA-based intratumoral immunotherapies in the US, have an RSI of 34.75.
On April 26th, 2018, OncoSec Medical announced that it will present at the American Society of Clinical Oncology 2018 Annual Meeting, which will be held from June 01st, 2018 to June 05th, 2018, in Chicago, Illinois. The Company will present a trial-in-progress poster presentation from its global, multi-center, registration-directed, open-label Phase-2b clinical trial, PISCES/KEYNOTE-695, assessing its investigational therapy, ImmunoPulse® IL-12, and the approved anti-PD-1 therapy pembrolizumab, in patients with unresectable metastatic melanoma, who have progressed or are progressing on an anti-PD-1 therapy. Wall St. Equities' research coverage also includes the downloadable free report on ONCS at: www.wallstequities.com/registration/?symbol=ONCS
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/free-research-reports-on-these-biotech-stocks----mannkind-marinus-pharma-mirati-therapeutics-and-oncosec-medical-300642754.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!